Topical tofacitinib for the treatment of alopecia areata affecting facial hair

Alopecia areata (AA) is a common autoimmune condition which can affect any hair-bearing site. Recent studies have demonstrated the effectiveness of Janus kinase inhibitors (JAKis) in the treatment of AA. Most studies documenting response of AA affecting facial hair to JAKi therapy involve oral administration due to extensive concomitant scalp involvement. However, oral JAKis are associated with adverse effects, e.g. infections, in 2-6% of patients. Topical JAKis may offer a safer alternative for limited disease, or in cases where systemic therapy is contraindicated or not desired.